1. Medicines
  2. Cardiology
  3. ENTRESTO
  4. Chronic HFrEF disease trajectory
  5. For hospitalised and outpatient

Click here for Prescribing Information

For Hospitalised & Outpatient Chronic HFrEF patients

________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

ENTRESTO is indicated in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction. It is the first-in-class ARNI recommended for the treatment of chronic HFrEF and targets two essential pathways in a complementary manner.

To learn more, review the Summary of Product Characteristics.

Start with ENTRESTO® to see benefits and keep patients out of the hospital longer vs ACEi (enalapril)1–7

ENTRESTO as first choice keeps patients out of the hospital longer vs ACEi (enalapril)1,5,6

Regardless of where patients are in their journey, starting ENTRESTO as early as possible improves outcomes vs ACEi (enalapril).1,5,6
 

graph 1

 

Start with ENTRESTO to maximise near and long-term benefits for your patients1,5,6

 

 

graph 2

 

ENTRESTO is indicated in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction.8

Discover the benefits of ENTRESTO vs ACEi (enalapril) in improving your chronic HFrEF patient’s treatment experience9,10

down pointing arrow icon

 

Patients in the PIONEER-HF/TRANSITION trial were required to be haemodynamically stabilised from an ADHF episode while in hospital.1,3

 

 

Starting ENTRESTO now reduces HF hospitalisations, saving hospital budgets and alleviating system burden11

PARADIGM-HF (N=8,442): Lower risk of CV death or HF hospitalisation with ENTRESTO vs ACEi12
 

graph 1

 

In a post hoc analysis, ENTRESTO reduced the relative risk of sudden cardiac death by 20% vs enalapril (P=0.0082)13

Discover the benefits of ENTRESTO vs ACEi (enalapril) in improving your chronic HFrEF patient’s treatment experience9,10

down pointing arrow icon

 

Summary of the safety profile

The most commonly reported adverse events (AEs) during treatment with ENTRESTO were hypotension (17.6%), hyperkalaemia (11.6%) and renal impairment (10.1%). Angioedema was reported in patients treated with sacubitril/valsartan (0.5%).8

Common AE:
Anaemia, hypokalaemia, hypoglycaemia, dizziness, headache, syncope, vertigo, orthostatic hypotension, cough, diarrhoea, nausea, gastritis, renal failure (renal failure, acute renal failure), fatigue, asthenia.8

Very common AE:
Hyperkalaemia, hypotension, renal impairment.8

Adverse reactions are ranked by System organ class and then by frequency with the most frequent first, using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).

 

Please click here for safety information

 

ACEi, angiotensin-converting enzyme inhibitor; ARNI, angiotensin receptor neprilysin inhibitor; CI, confidence interval; CV, cardiovascular;HFrEF, heart failure with reduced ejection fraction; HR, hazard ratio;LVAD, left ventricular assist device;NT-proBNP, N-terminal-pro-brain natriuretic peptide; NNT, number needed to treat; RR, risk reduction.

References:

  1. Velazquez EJ, et al. N Engl J Med 2019;380(6):539–548.
  2. Wachter R, et al. Eur J Heart Fail 2019;21(8):998–1007.
  3. Senni M, et al. Eur J Heart Fail 2019;22(2):303–312.
  4. Januzzi JL Jr, et al. JAMA 2019;322(11):1085–1095.
  5. DeVore AD, et al. Initiation of angiotensin-neprilysin inhibition after acute decompensated heart failure: results of the openlabel extension of the PIONEER-HF trial. Data presented at American College of Cardiology 68th Annual Scientific Session, March 2019.
  6. Morrow DA, et al. Circulation 2019;139(19):2285–2288.
  7. Maddox TM, et al. J Am Coll Cardiol 2021;77:772–810.
  8. ENTRESTO Summary of Product Characteristics. www.medicines.ie
  9. Chandra A, et al. JAMA Cardiol 2018;3(6):498–505.
  10. Lewis EF, et al. Circ Heart Fail 2017;10(8):e003430.
  11. Gaziano TA, et al. JAMA Cardiol 2020;5(11):1236–1244.
  12. McMurray JJ, et al. N Engl J Med 2014;371:993–1004.
  13. Desai AS, et al. Eur Heart J. 2015;36(30).
     

 

Rate this content: 
Average: 4.5 (2 votes)
December 2024 | IE225967-1
Print
×

Ask Speakers

×

Medical Information Request

Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.